Investor Relationship Services

Reviewing manufacturing feasibility (CMC, scalability, reproducibility, QC/QA risks).

Cross-checking scientific claims against the broader literature and competitor pipelines.

Independent review of the science and clinical rationale behind a company’s platform or assets.

Market sizing (TAM/SAM/SOM) and indication prioritization.

Competitive landscape analysis (pipeline maps, differentiators, risk of crowding).

Strategic fit: where the company’s platform could expand or partner.

Supporting screening of investment opportunities (sorting hype from credible science).

Preparing independent reports for investment committees.

Valuation support: connecting scientific milestones to value inflection points.

Training investment teams on technical topics (e.g., CAR-NK vs CAR-T vs γδ).

Advising on fund strategy in emerging modalities (iPSC, in vivo gene editing, AI-driven discovery).

Acting as a fractional scientific affairs partner to funds without in-house deep CGT expertise.

Labyrinth CGT Consulting, LLC